Can I Choose Endoscopy Over Stomach Removal for HDGC?
At a Glance
While the Cambridge Protocol endoscopy can delay surgery, prophylactic total gastrectomy (stomach removal) remains the gold standard for CDH1 mutations. Removing the entire stomach is the only way to completely eliminate the high risk of hereditary diffuse gastric cancer.
In this answer
5 sections
If you have a CDH1 mutation, you are at a significantly higher risk of developing hereditary diffuse gastric cancer (HDGC). Because of this risk, it is common to wonder if you can just get frequent endoscopies instead of having your entire stomach removed. The short answer is that while rigorous endoscopic surveillance—often referred to as the Cambridge Protocol—is an option to delay surgery, it is not considered as safe as surgery. Prophylactic total gastrectomy (PTG), or the surgical removal of the stomach before cancer develops, remains the medical gold standard because it is the only way to completely eliminate the risk of this aggressive cancer [1][2].
Understanding why experts recommend surgery over surveillance requires looking at how diffuse gastric cancer grows and the limitations of even the most advanced endoscopy techniques.
The Challenge of Diffuse Gastric Cancer
Unlike many stomach cancers that form a visible tumor or mass, diffuse gastric cancer is insidious. It begins as microscopic clusters of abnormal cells (known as signet ring cell carcinomas) that spread out just beneath the surface of the stomach lining [3][4]. Because these clusters grow under the surface, the stomach lining often looks completely normal on a standard endoscopy.
This unique growth pattern makes finding diffuse gastric cancer incredibly difficult, even for experienced gastroenterologists.
The Cambridge Protocol: Endoscopic Surveillance
For patients who choose to delay surgery, or who are not yet candidates for surgery, doctors use a highly specialized screening method called the Cambridge Protocol [5][3].
This is not a standard endoscopy. The Cambridge Protocol involves:
- Carefully washing and inflating the stomach to inspect the lining for very subtle changes in color (pale mucosal areas) [6].
- Taking exactly 30 random biopsies (tissue samples)—typically 5 samples from 6 distinct anatomical zones of the stomach—along with targeted biopsies of any suspicious spots [3][7].
The Risks of Surveillance
While the Cambridge Protocol is the best available screening tool, it has significant limitations. Because it relies on taking tiny samples of a large organ, it can easily miss the microscopic, scattered clusters of cancer cells [8][2].
Studies have shown that endoscopic surveillance, even when using advanced protocols, frequently fails to detect early-stage cancer [9][10]. In fact, one study found that when patients who had been monitored with the Cambridge Protocol eventually had their stomachs removed, cancer was found in the removed stomach tissue that the endoscopies had missed [3][8].
Therefore, choosing surveillance means living with the ongoing risk that cancer could be developing undetected [2].
Prophylactic Total Gastrectomy: The Gold Standard
Because individuals with a germline CDH1 mutation have a very high lifetime risk (up to 60-80%) of developing diffuse gastric cancer, prophylactic total gastrectomy (PTG) is the recommended standard of care [11][1]. By removing the entire stomach, the risk of developing gastric cancer is eliminated [12][13]. For individuals with a strong family history, this surgery is typically recommended between the ages of 20 and 30 [1][10].
Life After Surgery
A total gastrectomy is a massive, life-altering surgery. Without a stomach, the esophagus is connected directly to the small intestine. This requires permanent, significant changes to how you eat and digest food.
- Eating Habits and “Dumping Syndrome”: You will no longer be able to eat standard-sized meals. Daily life involves eating 6 to 8 very small meals a day and avoiding drinking liquids while eating. A common consequence is dumping syndrome, where food moves too quickly into the small intestine, causing cramps, nausea, dizziness, and diarrhea. This is typically managed by modifying your diet to avoid simple sugars and carbohydrates [14][15].
- Nutritional Impacts and Weight Loss: It is very common to experience durable weight loss that typically stabilizes 6 to 12 months after the surgery. Patients also face potential vitamin and mineral deficiencies (like Vitamin B12) [14][16]. Working closely with a registered dietitian is essential to maintain nutrition [17].
- Quality of Life: The recovery is difficult, and patients can experience challenges with eating habits, body image, and mental health [18][19]. It is highly recommended to connect with a psychological counselor or a CDH1 patient support group (such as No Stomach For Cancer). However, long-term quality of life is generally reported as good. Many patients view the benefit of eliminating their cancer risk as outweighing the adverse effects of the surgery, and report outcomes as being good or better than they expected before surgery [20][21].
Additional CDH1 Risks
While managing gastric cancer risk is paramount, it is also important to know that CDH1 mutations carry a significantly elevated risk for lobular breast cancer in women [22][23]. Comprehensive management of a CDH1 mutation requires rigorous breast cancer surveillance (such as annual breast MRIs) for female patients [24].
Making Your Decision
The decision between prophylactic surgery and endoscopic monitoring is incredibly personal and should be tailored to your specific family history and preferences [5][25]. For example, if you were found to have a CDH1 mutation through a genetic panel but do not have a strong family history of the disease, your individual risk might be lower, which could factor into your timeline for surgery [26][27].
Because this condition is complex, your care should be managed by a multidisciplinary team—including surgical oncologists, gastroenterologists, clinical geneticists, and dietitians—who specialize in hereditary cancer syndromes [17][23].
Common questions in this guide
Can I just get frequent endoscopies instead of having my stomach removed for HDGC?
What is the Cambridge Protocol?
Why is prophylactic total gastrectomy the standard of care?
What is life like after having your stomach removed?
Do CDH1 mutations increase the risk for other cancers?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.If I choose to delay surgery and use the Cambridge Protocol, how experienced is your endoscopy team at performing this exact 30-biopsy surveillance?
- 2.Based on my specific mutation and family history, what is my personal recommended timeline for a prophylactic total gastrectomy?
- 3.How many prophylactic total gastrectomies has this surgical team performed for CDH1 mutation carriers?
- 4.Can you connect me with a registered dietitian who specializes in post-gastrectomy nutrition and dumping syndrome?
- 5.Can you connect me with another patient who has had this surgery so I can learn about their day-to-day experience?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (27)
- 1
Panel testing reveals nonsense and missense CDH1 mutations in families without hereditary diffuse gastric cancer.
Huynh JM, Laukaitis CM
Molecular genetics & genomic medicine 2016; (4(2)):232-6 doi:10.1002/mgg3.197.
PMID: 27064202 - 2
Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations.
Kumar S, Katona BW, Long JM, et al.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2020; (18(2)):505-508.e1 doi:10.1016/j.cgh.2019.04.064.
PMID: 31077828 - 3
Random biopsies in patients harboring a CDH1 mutation: time to change the approach?
Castro R, Lobo J, Pita I, et al.
Revista espanola de enfermedades digestivas 2020; (112(5)):367-372 doi:10.17235/reed.2020.6720/2019.
PMID: 32338015 - 4
Evaluation of confocal laser endomicroscopy for detection of occult gastric carcinoma in CDH1 variant carriers.
Schueler SA, Gamble LA, Curtin BF, et al.
Journal of gastrointestinal oncology 2021; (12(2)):216-225 doi:10.21037/jgo-20-430.
PMID: 34012620 - 5
Hereditary Diffuse Gastric Cancer Syndrome and the Role of CDH1: A Review.
Gamble LA, Heller T, Davis JL
JAMA surgery 2021; (156(4)):387-392 doi:10.1001/jamasurg.2020.6155.
PMID: 33404644 - 6
Factors associated with detection of hereditary diffuse gastric cancer on endoscopy in individuals with germline CDH1 mutations.
Laszkowska M, Tang L, Vos E, et al.
Gastrointestinal endoscopy 2023; (98(3)):326-336.e3 doi:10.1016/j.gie.2023.04.2071.
PMID: 37094689 - 7
Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study.
Lee CYC, Olivier A, Honing J, et al.
The Lancet. Oncology 2023; (24(1)):107-116 doi:10.1016/S1470-2045(22)00700-8.
PMID: 36509094 - 8
Gastroscopic surveillance with targeted biopsies compared with random biopsies in CDH1 mutation carriers.
van Dieren JM, Kodach LL, den Hartog P, et al.
Endoscopy 2020; (52(10)):839-846 doi:10.1055/a-1157-8678.
PMID: 32408363 - 9
Chromoendoscopy in combination with random biopsies does not improve detection of gastric cancer foci in CDH1 mutation positive patients.
Hüneburg R, Marwitz T, van Heteren P, et al.
Endoscopy international open 2016; (4(12)):E1305-E1310 doi:10.1055/s-0042-112582.
PMID: 27995193 - 10
Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer.
Shepard B, Yoder L, Holmes C
ACG case reports journal 2016; (3(4)):e179 doi:10.14309/crj.2016.152.
PMID: 28008412 - 11
Outcomes after prophylactic gastrectomy for hereditary diffuse gastric cancer.
van der Kaaij RT, van Kessel JP, van Dieren JM, et al.
The British journal of surgery 2018; (105(2)):e176-e182 doi:10.1002/bjs.10754.
PMID: 29341148 - 12
Pioneering use of genetic analysis for CDH1 to identify candidates for prophylactic total gastrectomy to prevent hereditary diffuse gastric cancer.
Mokhtari-Esbuie F, Szeglin B, Ravari MR, et al.
eGastroenterology 2023; (1(2)) doi:10.1136/egastro-2023-100017.
PMID: 38188186 - 13
Diagnosis and Management of Hereditary Gastric Cancer.
Monahan KJ, Hopkins L
Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2016; (205()):45-60 doi:10.1007/978-3-319-29998-3_4.
PMID: 27075348 - 14
Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients.
Strong VE, Gholami S, Shah MA, et al.
Annals of surgery 2017; (266(6)):1006-1012 doi:10.1097/SLA.0000000000002030.
PMID: 27759617 - 15
The Psychological Impact of Prophylactic Total Gastrectomy in Patients Who Are High Risk for Hereditary Diffuse Gastric Cancer: A Review of the Literature.
Hayat MY, Yakubu U, Jayasinghe J, Patel B
Cureus 2025; (17(5)):e84751 doi:10.7759/cureus.84751.
PMID: 40551901 - 16
Efficacy of Long-Term Oral Vitamin B12 Supplementation after Total Gastrectomy: Results from a Prospective Study.
Moleiro J, Mão de Ferro S, Ferreira S, et al.
GE Portuguese journal of gastroenterology 2018; (25(3)):117-122 doi:10.1159/000481860.
PMID: 29761147 - 17
Emerging Adults Carrying a CDH1 Pathogenic or Likely Pathogenic Variant Face Diet and Lifestyle Challenges after Total Gastrectomy.
Liu Y, Lopez R
Journal of the Academy of Nutrition and Dietetics 2022; (122(5)):913-917 doi:10.1016/j.jand.2021.12.012.
PMID: 34968751 - 18
Psychosocial Impacts of Prophylactic Total Gastrectomy for Hereditary Diffuse Gastric Cancer: A Narrative Review.
Kearns O, Snyder D, Davis J, et al.
Psycho-oncology 2025; (34(10)):e70304 doi:10.1002/pon.70304.
PMID: 41130910 - 19
Nutritional Experiences of Patients Undergoing Total Gastrectomy Surgery: A Qualitative Study.
Şayır D, Karacabay K
Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates 2024; (47(3)):203-212 doi:10.1097/SGA.0000000000000800.
PMID: 38847430 - 20
Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery.
Kaurah P, Talhouk A, MacMillan A, et al.
Familial cancer 2019; (18(4)):429-438 doi:10.1007/s10689-019-00133-9.
PMID: 31273560 - 21
The Psychosocial Impact of Undergoing Prophylactic Total Gastrectomy (PTG) to Manage the Risk of Hereditary Diffuse Gastric Cancer (HDGC).
Hallowell N, Lawton J, Badger S, et al.
Journal of genetic counseling 2017; (26(4)):752-762 doi:10.1007/s10897-016-0045-8.
PMID: 27837291 - 22
Germline CDH1 Variants and Lifetime Cancer Risk.
Ryan CE, Fasaye GA, Gallanis AF, et al.
JAMA 2024; (332(9)):722-729 doi:10.1001/jama.2024.10852.
PMID: 38873722 - 23
Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report.
Mirandola S, Pellini F, Granuzzo E, et al.
International journal of surgery case reports 2019; (58()):92-95 doi:10.1016/j.ijscr.2019.03.053.
PMID: 31028995 - 24
Defining features of hereditary lobular breast cancer due to CDH1 with magnetic resonance imaging and tumor characteristics.
Gamble LA, McClelland PH, Teke ME, et al.
NPJ breast cancer 2023; (9(1)):77 doi:10.1038/s41523-023-00585-4.
PMID: 37758801 - 25
Hereditary diffuse gastric cancer: updated clinical practice guidelines.
Blair VR, McLeod M, Carneiro F, et al.
The Lancet. Oncology 2020; (21(8)):e386-e397 doi:10.1016/S1470-2045(20)30219-9.
PMID: 32758476 - 26
Clinical approach for managing patients with unexpected CDH1 mutations: A case report.
Garitaonaindia Y, Méndez M, Valentín F, et al.
Molecular genetics & genomic medicine 2024; (12(7)):e2496 doi:10.1002/mgg3.2496.
PMID: 39056403 - 27
Early genetic counseling and detection of CDH1 mutation in asymptomatic carriers improves survival in hereditary diffuse gastric cancer.
Moslim MA, Heald B, Tu C, et al.
Surgery 2018; (164(4)):754-759 doi:10.1016/j.surg.2018.05.059.
PMID: 30145018
This page explains surgical and surveillance options for HDGC for educational purposes only. Always consult a genetic counselor, surgical oncologist, or gastroenterologist regarding your specific CDH1 mutation and treatment timeline.
Get notified when new evidence is published on diffuse gastric adenocarcinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.